Novartis Institutes for BioMedical Research (NIBR) Risk Report

⚖️ Legal & Regulatory

Novartis faces several legal and regulatory challenges that present potential risks to its operations. The company is involved in litigation and regulatory scrutiny, which could lead to financial liabilities or penalties. It is critical for Novartis to address these issues to mitigate any adverse effect on its business stability and reputation.

• Novartis, along with Viatris, is facing a lawsuit over claims of misuse of 'HeLa' cells 🗓 August 5, 2024.
• A row in Greece was sparked after Novartis probe witnesses were exposed 🗓 October 26, 2024.
• The US Supreme Court rebuffed Novartis's bid to revive the Gilenya patent, impacting the company's intellectual property rights 🗓 April 17, 2023.
• A judge blocked West Virginia's 340B contract pharmacy law, which involves Novartis 🗓 December 19, 2024.

📜 Innovation & R&D

Novartis Institutes for Biomedical Research (NIBR) is actively engaged in innovative research and development collaborations, indicating a strong commitment to advancing medical science. Strategic partnerships and acquisitions are likely to fuel further pharmacological breakthroughs and market growth.

• Novartis announced an up-to-$1 billion collaboration with Generate: Biomedicines to develop AI protein drugs 🗓 September 24, 2024.
• The FDA approved Novartis' Kisqali as a first-line breast cancer treatment 🗓 April 7, 2025.
• Novartis acquired Regulus, a kidney disease drug maker, in a deal valued up to $1.7 billion 🗓 April 30, 2025.
• Novartis implemented a name change for its research labs to signify strategic shifts in research focus 🗓 September 8, 2023.
• Oncology research remains a focal point for Novartis as detailed in their announcements on 🗓 July 18, 2024.